HC Wainwright Begins Coverage on AgomAb Therapeutics (NASDAQ:AGMB)

Research analysts at HC Wainwright initiated coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report issued on Monday,Benzinga reports. The firm set a “buy” rating on the stock.

Several other brokerages also recently issued reports on AGMB. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research report on Wednesday, March 4th. Morgan Stanley began coverage on shares of AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 target price on the stock. Finally, Leerink Partners started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, AgomAb Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $32.00.

AgomAb Therapeutics Stock Performance

AGMB stock opened at $10.98 on Monday. The company has a 50 day moving average of $10.96. AgomAb Therapeutics has a 1 year low of $8.75 and a 1 year high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.